venBio Global Strategic Fund IV, L.P.
CIK: 0001862109
venBio Global Strategic Fund IV, L.P.'s purchase track record
venBio Global Strategic Fund IV, L.P. has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/6/2026 | ATTO | $6.50M | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ATTO | ▼ Sell | Other | 2,311,870 | — | 8/6/2026 | View on chart |
| ATTO | ▲ Buy | Open Market | 382,352 | $6.5M | 8/6/2026 | View on chart |
| ATTO | ▼ Sell | Other | 665,147 | — | 8/6/2026 | View on chart |
| ATTO | ▼ Sell | Other | 821,998 | — | 8/6/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ATTO shares dip as investors question valuation after cancer vaccine news
Attovia Therapeutics' stock moved lower as investors raised concerns about whether its current valuation is justified. The scrutiny comes as the broader oncology space sees attention, highlighted by recent discussion of Moderna's cancer vaccine development. The stock is trading near the lower end of its 52‑week range, with RSI indicating modest momentum.
ATTO shares dip as investors question valuation after cancer vaccine news. Attovia Therapeutics' stock moved lower as investors raised concerns about whether its current valuation is justified. The scrutiny comes as the broader oncology space sees attention, highlighted by recent discussion of Moderna's cancer vaccine development. The stock is trading near the lower end of its 52‑week range, with RSI indicating modest momentum.